Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.
Testicular cancer statistics
New cases of testicular cancer, 2015, UK
Deaths from testicular cancer, 2016, UK
Survive testicular cancer for 10 or more years, 2010-11, England and Wales
Preventable cases of testicular cancer are not known as it is not clearly linked to any preventable risk factors
- There are around 2,300 new testicular cancer cases in the UK every year, that's more than 6 every day (2013-2015).
- In males in the UK, testicular cancer is the 17th most common cancer, with around 2,300 new cases in 2015.
- Testicular cancer accounts for 1% of all new cancer cases in males in the UK (2015).
- Incidence rates for testicular cancer in the UK are highest in males aged 30 to 34 (2013-2015).
- Since the early 1990s, testicular cancer incidence rates have increased by more than a quarter (27%) in males in the UK.
- Over the last decade, testicular cancer incidence rates have increased by a tenth (10%) in males in the UK.
- Around 1 in 10 testicular cancer cases are diagnosed at a late stage in Northern Ireland (2010-2014).
- Most testicular cancers occur in descended testicles.
- Incidence rates for testicular cancer are projected to rise by 12% in the UK between 2014 and 2035, to 10 cases per 100,000 males by 2035.
- 1 in 195 men will be diagnosed with testicular cancer during their lifetime.
- Testicular cancer in England is less common in males living in the most deprived areas.
- Testicular cancer is more common in White males than in Asian or Black males.
- An estimated 34,900 men who had previously been diagnosed with testicular cancer were alive in the UK at the end of 2010.
- In Europe, around 21,500 new cases of testicular cancer were estimated to have been diagnosed in 2012. The UK incidence rate is 19th highest in Europe.
- Worldwide, around 55,300 new cases of testicular cancer were estimated to have been diagnosed in 2012, with incidence rates varying across the world.
- There are around 60 testicular cancer deaths in the UK every year, that's around 1 every week (2014-2016).
- In males in the UK, testicular cancer is not among the 20 most common causes of cancer death, with around 55 deaths in 2016.
- Testicular cancer accounts for less than 1% of all cancer deaths in males in the UK (2016).
- Mortality rates for testicular cancer in the UK are highest in males aged 50 to 54 (2014-2016).
- Since the early 1970s, testicular cancer mortality rates have decreased by more than four-fifths (83%) in males in the UK.
- Over the last decade, testicular cancer mortality rates have decreased by more than a quarter (29%) in males in the UK.
- Mortality rates for testicular cancer are projected to fall by 35% in the UK between 2014 and 2035, to fewer than 1 death per 100,000 males by 2035.
- Testicular cancer deaths in England are more common in males living in the most deprived areas.
- In Europe, around 1,600 men were estimated to have died from testicular cancer in 2012. The UK mortality rate is eighth lowest in Europe.
- Worldwide, around 10,400 men were estimated to have died from testicular cancer in 2012, with mortality rates varying across the world.
- Almost all (98%) men diagnosed with testicular cancer in England and Wales survive their disease for ten years or more (2010-11).
- Almost all (98%) men diagnosed with testicular cancer in England and Wales survive their disease for five years or more (2010-11).
- Around all (99%) men diagnosed with testicular cancer in England and Wales survive their disease for one year or more (2010-11).
- Almost all men in England diagnosed with testicular cancer aged 15-49 survive their disease for five years or more, compared with more than two-thirds of men diagnosed aged 80 and over (2009-2013).
- Testicular cancer survival is improving and has increased in the last 40 years in the UK, probably because of combination chemotherapy.
- In the 1970s, around 7 in 10 men diagnosed with testicular cancer survived their disease beyond ten years, now it's around all men.
- When diagnosed at its earliest stage, all men with testicular cancer will survive their disease for five years or more, compared with around 8 in 10 men when diagnosed at the latest stage.
- Five-year relative survival for testicular cancer in men is above the European average in England but similar to the European average in Wales, Scotland and Northern Ireland.
- A person’s risk of developing cancer depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
- Testicular cancer is not clearly linked to any preventable risk factors.
- No modifiable factors have been conclusively linked with testicular cancer risk, though many factors have been studied. The most well-established risk factor for testicular cancer is cryptorchidism.
- 'Two-week wait' is the most common route to diagnosing testicular cancer.
- ‘Two-week wait’ standards are met by all countries, ‘31-day wait’ and ‘62 day wait’ are not met by any country for urological cancers.
The latest statistics available for testicular cancer in the UK are; incidence 2015, mortality 2016 and survival 2010-2011 (all ages combined) and 2009-2013 (by age).
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2012.
Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages,
Survival by stage is not yet routinely available for the UK due to inconsistencies in the collecting and recording of staging data in the past. Survival by stage is available for the former Anglia Cancer Network in the east of England, however. The former Anglia Cancer Network covers around 5% of the population of England and may not be representative of the country as a whole due to differences in underlying demographic factors (such as age, deprivation or ethnicity), as well as variation in local healthcare provision standards and policies.
Routes to diagnosis statistics were calculated from cases of cancer registered in England which were diagnosed in 2012-2013.
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Testicular cancer is part of the group 'Urological cancer' for cancer waiting times data. Codes vary per country but broadly include: penis, prostate, testis, other and unspecified male genital organs, kidney, renal pelvis, ureter, bladder, other and unspecified urinary organs, secondary cancers of kidney, renal pelvis, bladder and other unspecified urinary organs.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.
You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.
When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or
We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.